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Aim. To study ssociation of the FGFR2 and TOX3/LOC643714 genetic polymorphisms with 
the BRCA1/2 mutation status in Ukrainian female breast cancer patients without ionizing ra-
diation impact in their histories. Methods. Molecular genetics methods were used. Non-
parametric data were evaluated using the two-way Fisher’s Exact test. Statistical analysis was 
performed using the StatPlus Pro program package. Results. Association of genetic polymor-
phisms rs2981582 of the FGFR2 gene and rs3803662 of the TOX3/LOC643714 gene with the 
mutation status of the BRCA1/2 genes in breast cancer patients non-treated with ionizing ra-
diation in their histories was shown. The association between the minor genotype of the TOX3/
LOC643714 gene and the positive status of the BRCA1 gene was found to be reliable. No 
statistic association was found between homozygotes for the major alleles and heterozygote 
polymorphisms of the FGFR2, TOX3 / LOC643714 genes, with or without BRCA1/2 muta-
tions (p < 0.05).
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Breast cancer is the most commonly occurring 
cancer among women world wide [1]. In 
Ukraine it accounts for over 20 % of all ma-
lignant tumors and is the second most frequent 
cause of cancer-related death [2]. 
Despite the fact that most cases of breast 
cancer are sporadic, 25 % of them are associ-
ated with hereditary inheritance factors of high 
penetrance genes for the development of breast 
cancer, and family history remains the best 
indicator of their individual risk [3]. Among 
the known predisposition genes, the BRCA1 
and BRCA2 mutations have the strongest influ-
ence on the susceptibility of the disease and 
the risk of developing breast cancer to 85 % 
of the mutation carriers [4, 5].
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Though the effect of high penetrance gene 
mutations is noticeable, they account for only 
about 25 % of family risk and less than 5 % 
of the overall incidence of breast cancer, since 
their frequency in the general population is 
very low [6]. As a result of the combination of 
several common low penetrance genes, each 
of which increases the risk of breast cancer, 
the odds ratio (OR) is 1.2–1.5 [7.8]. According 
to the polygonal model of inheritance, a large 
number of low penetrance genes may have a 
communicative effect on the risk [9] and the 
disease manifestation [10, 11].
Single nucleotide polymorphism (SNPs) 
associated with the risk of various types of 
cancer has been identified through Genome-
wide association study (GWAS). More than 
22 studies have been conducted to study 
breast cancer in different populations, where 
more than 36 loci have been associated with 
the hereditary predisposition to this di se-
ase [12].
Antoniou A. et al. suggested that the he-
reditary predisposition to breast cancer in the 
carriers of mutations in the BRCA1 and BRCA2 
genes may be explained in a polygenic model 
with a large number of low penetrance alleles, 
each of which slightly increases the risk, but 
their cumulative effect becomes quite pro-
nounced [13]. The hypothesis “common dise-
ase – common variant” was formulated, ac-
cording to which the hereditary predisposition 
to common diseases (including oncology) is 
caused by many genetic variants, often found 
in the population [14].
GWAS has identified the genetic suscepti-
bi lity loci associated with breast cancer risk 
[15–17]. Today low penetrance SNPs [18] with 
a weak association with the breast cancer risk 
compared to high penetrance mutations such 
as BRCA1 or BRCA2 is identified [19]. Though 
each option with low penetrance gives only a 
small increase in breast cancer, a combination 
of individual choices can act cumulatively 
leading to an increased risk (some of which 
are listed in Table 1). Such combinations may 
be useful tools for the identification of women 
with relative risk and prevention in the popu-
lation. Relations likely are situated in the range 
of 1.1–1.3 and 1.2–1.6 for hetero- and homo-
zygous genotypes respectively [8, 23, 24]. The 
important fact is that although mutations in the 
genes BRCA1, BRCA2 cause an increased risk 
of breast cancer, Baynes S. demonstrated that 
there is no association between genetic poly-
morphisms and mutations in the genes BRCA1, 
BRCA2 (separately and in combination) with 
the risk of breast cancer [17, 25].
The aim of the work was to establish the 
association of genetic polymorphisms of the 
FGFR2, TOX3 / LOC643714 genes carriership 
with mutation status of the BRCA1/2 genes in 
Ukrainian women with breast cancer who do 
not have an ionizing radiation history.
Methods
Patients. The main group of patients was 
formed from 62 women aged 35-60 and diag-
nosed to have breast cancer, which was con-
firmed histologically. To determine the speci-
fics of the clinical course of the disease, the 
history of the disease and medical records of 
the patients were studied; the computer data-
base was created. The study included women 
without ionizing radiation and anamnesis. The 
studied cohort of women was divided accord-
ing to their mutated status into BRCA1/2positive 
and negative ones. For molecular genetic stu-
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dies, the samples of peripheral blood were 
used. 
DNA isolation. DNA isolation was carried 
out with the standard method using the 
NeoPrep100 DNA Magnet kit (NeoGene, 
Ukraine). Also, the genomic DNA was ex-
tracted from formalin-fixed and paraffin-em-
bedded tissues using a Quiamp DNA Mini Kit 
DNA kit (Quiagen, Hilden, Germany). 
Allelic-specific PCR. The genotyping of the 
polymorphic markers rs2981582 of the gene 
FGFR2 and rs3803662 of the TOX3 / LOC643714 
gene was performed by allelic-specific PCR with 
real-time detection on the LightCycler II ampli-
fier (Roche, Switzerland) using specific primers 
and probes. The probes have a fluorescence 
modification and a gummy dye (quencher) that 
suppresses fluorescence until the DNA poly-
merase, due to its exonuclear activity, releases 
fluorochrome in the process of elongating the 
PCR product. Each step was accompanied by the 
registration of the fluorescence signal in the 
bands corresponding to fluorores fluorescence 
intervals. Primers for the determination of the 
studied polymorphisms of the FGFR2, TOX3 / 
LOC643714 genes synthesized by the TIB 
MOLBIOL company (Germany) are presented 
in Table 2.
The reaction mixture consisted of probes 
manufactured by Roche Diagnostics (Ger ma-
ny). Amplification was performed under the 
following conditions: initial denaturation for 
10 min at 95 °C; 45 amplification cycles that 
exponentially increase the number of ampli-
Table 1. SNPs – low penentrance markers of genetic predisposition to breast cancer with BRCA1 and 
BRCA2 gene mutations carriers 
Polymo-
rphism Locus Gene Protein function
OR for 
minor allele
Association in different 
groups of patients
Risk modification 
in the BRCA1 
and BRCA2 gene 
mutations carriers 
[20, 21]
BRCA1 BRCA2
rs2981582 10q26 FGFR2
recipe for 
growth of 
fibroblasts
1,26 [8, 17]
Breast cancer in postme-
no pause [17], stronger 
associations with ER-
positive and PR-positive 
breast tumors [22]
no  yes
rs3803662 16q12.1 TOX3
DNA-depen dent 
regulation of the 
transcription
1,28[23]
1,20[8]
Stronger associations 
with ER-positive breast 
tumors [23]
yes yes
Table 2. Primers to define the genes FGFR2, TOX3/LOC643714 polymorphisms being studied
Polymorphism Primer Sequence (5’ ® 3’)
rs2981582 of the FGFR2 gene
Upstream CATCGCCACTTAATGAACCTGTTTG
Downstream GGAGAGTCCACCTGGTGCCTGCCTG
rs3803662 of the TOX3/LOC643714 gene
Upstream CTCTCCTTAATGCCTCTATAGCTGTC
Downstream CTTAGCGAAGAATAAAACTGTGGAC
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cons for molecular analysis and include dena-
turation at 95 °C – 10 sec, reoccurring at 60 
°C – 10 sec, synthesis at 72 °C 15 sec; melting 
at 95 °C – 20 sec, 40 °C – 40 sec; cooling at 
40 °C – 30 sec.
At the end of the amplification reaction, the 
accounting and analysis of the results were 
made in accordance with the manufacturer‘s 
recommendations.
The search for mutations was done using 
the PCR method and the analysis of the melt-
ing point Tm of the amplicons obtained. The 
PCR reaction was performed using TIB 
MOLBIOL (Germany) reagents. The dis-
placement of Tm indicated changes in the 
nucleic acid sequence of the amplicon. The 
Tm analysis was performed using Light 
Cycler Software (build 4.1.1.21.) (Roche, 
Switzerland).
Statistic. The obtained results were processed 
using variation statistic methods, adopted for 
biological research and recommended for the 
processing of the results of molecular genetic 
studies using the StatPlus Pro package.
Results
Antoniou A. C. and Easton D. F. made the hy-
pothesis that the risk of developing breast can-
cer in the carriers of mutations in the BRCA1 
and BRCA2 genes is modified by genetic fac-
tors [7]. The multicentre studies conducted by 
Antoniou A.C. et al. who included in total more 
than 25,000 mutation carriers in the BRCA1 and 
BRCA2 [20, 21] genes showed a modifying role 
of the common low penetrance genetic variants 
associated with the risk of development in the 
general population (Table 1) .
It is important that the relative risk for these 
genetic variants in the group of patients with 
mutations in the BRCA1 and BRCA2 genes 
coincides with the risk for the population as a 
whole, although it is a significant factor that 
modifies the risk of developing breast cancer. 
Thus, the data obtained most fit to a simple 
multiplicative interaction model, in which the 
effect of each variant is independent; the ac-
curate assessment of the risk is made taking 
into account the contribution of high-pene-
trance mutations [26]. Patients with mutations 
in the BRCA2 in postmenopause [17], stronger 
associations with ER-positive and PR-positive 
breast tumors [22].
As a result of molecular-genetic analysis of 
DNA in women with breast cancer without 
radiation history, the association of carriership 
of genetic polymorphisms rs2981582 of the 
FGFR2 gene, rs3803662 of the TOX3/
LOC643714 gene with mutation status of the 
genes BRCA1/2 was established.
Among the patients without breast cancer 
who had molecular genetic determination of 
genotypes of rs2981582 polymorphism of [the] 
FGFR2 gene, 5 of 62 subjects had positive 
status of the BRCA1 gene. The BRCA2 muta-
tions were not found in the studied cohort.
In the cohort of patients without a radiation 
history, which managed to successfully am-
plify the rs3803662 polymorphism of the 
TOX3 / LOC643714 gene, four BRCA1-
positive mutations were identified among 41 
patients. Instead, the BRCA2 mutation was not 
found in the studied group.
Having applied Fisher’s ratio test we man-
aged to calculate the association among the 
BRCA1 / 2 gene status indicators, depending 
on the variants of the genetic polymorphisms 
rs2981582 of the FGFR2 gene, rs3803662 of 
the TOX3 / LOC643714 gene. 
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We obtained the following results: Fisher’s 
ratio test with the association of genetic poly-
morphism rs2981582 of the FGFR2 gene and 
rs3803662 of the TOX3 / LOC643714 gene with 
positive status of the BRCA1 gene was 0.212, 
p < 0.05 and 0.028, p > 0.05, respectively.
No association of the rs2981582 genotypes 
of the FGFR2 gene with positive or negative 
status of the BRCA1/2 genes was found in the 
cohort of patients with breast cancer without 
ionizing radiation impact in their history.
Instead, we revealed an association with the 
BRCA1-positive status of the minor allele in 
the TT polymorphism rs3803662 of the TOX3 
/ LOC643714 gene among patients with breast 
cancer without ionizing radiation in their his-
tory (Fisher’s ratio test – 0.028, p > 0.05).
The results of the correlation of the genetic 
polymorphisms rs2981582 of the FGFR2 gene 
and rs3803662 of the gene TOX3 / LOC643714 
among patients with breast cancer without 
ionizing radiation in their history are pre sen ted 
in Table 4.
No statistic association was found among 
homozygotes for major alleles and heterozy-
gote polymorphisms of the FGFR2, TOX3 / 
LOC643714 genes, with or without BRCA1 / 
2 mutations (p < 0.05).
Thus, by comparing and analyzing the data 
of the molecular study, regarding the genetic 
polymorphism rs2981582 of the FGFR2 gene, 
with a positive and negative BRCA-status, no 
significant difference has been found between 
the indices.
According to the literature, the genetic poly-
morphism rs2981582 of the FGFR2 gene was 
significantly associated with the BRCA2 muta-
tion (p = 2 × 10-8) [27]. Latif et al. have also 
found that in the breast cancer patients who 
were TT genotype carriers the FGFR2 gene 
was associated with the positive status of the 
BRCA2 mutation.
In the mutation carriers, BRCA1 and BRCA2 
were associated with the genetic polymor-
phism rs3803662 of the TOX3 / LOC643714 
gene and an increased risk of breast cancer 
(p = 0.004 and 0.009 respectively) [28].
According to the Antoniou A. C. et al., re-
search for the rs2981582 polymorphisms of the 
Table 3. Distribution of genetic polymorphisms 
genotypes of rs2981582 of the FGFR2 gene, 
rs3803662 of the TOX3 / LOC643714 gene 
depending on the status of BRCA1/2 genes in 
women with breast cancer without ionizing 
radiation history
Breast 
cancer 
patients 
without 
IR in 
history
SNPs: rs2981582 rs3803662
Gene: FGFR2 TOX3/LOC643714
Number of 
Patients n=62 n=41
SNP 
genotypes: CC CT TT CC CT TT
BRCA-positive 3 0 2 0 1 3
BRCA-negative 25 23 9 26 5 6
Table 4. Frequency of genetic polymorphisms rs2981582 of the FGFR2 gene, rs3803662 of the TOX3/
LOC643714 gene in women with breast cancer without ionizing radiation history with different mutation 
status of the BRCA1/2 genes
Gene SNP V allele Fisher’s ratio test p
FGFR2 rs2981582 T 0,212 p < 0,05
TOX3/LOC643714 rs3803662 T 0,028 p > 0,05
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FGFR2 gene, an increased risk of breast cancer 
for BRCA2 mutation carriers was found [21]. 
In the study conducted in the Chilean population 
of women with a family history of breast cancer, 
a correlation was found between the minor al-
lele rs3803662 of the TOX3/LOC643714 gene 
with the risk of developing breast cancer (OR = 
1.57 95 % CI 1.25–1.95) [29].
However, in our study, we did not have 
patients with such mutations. According to the 
same authors, the close connection between 
the T/T genotype and the rs3803662 polymor-
phism of the TOX3/LOC643714 gene with a 
positive mutation status of the BRCA1 gene 
was proved, which was reflected in our study 
for spontaneous breast cancer (p = 0.03). The 
latter fact can be a consequence of the inher-
ited gene linkage.
Conclusions
The association of the TT rs3803662 genotype 
of the TOX3/LOC643714 gene with positive 
mutation status of the BRCA1 gene (p = 0.03) 
was observed in women with breast cancer 
without ionizing radiation in their history.
No association was found between homo-
zygotes for major alleles and heterozygote 
polymorphism of the TOX3 / LOC643714 
gene, and the presence or absence of the 
BRCA2 mutations (p < 0.05).
No statistic association was found among 
homozygotes for major alleles and heterozy-
gotes of the FGFR2 polymorphism, with or 
without mutations in the BRCA1 and BRCA2 
genes (p < 0.05).
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Визначення асоціації носійства генетичних 
поліморфізмів з мутаційним статусом генів 
brca1/2 при спонтанному раку молочноїзалози
С. І. Поліник, Л. А. Рибченко, С. В. Клименко, 
Л. М. Захарцева, Б. Т. Клімук
Мета. Визначення асоціації носійства генетичних 
поліморфізмів генів FGFR2, TOX3/LOC643714 з му-
таційним статусом генів BRCA1/2 у жінок України 
хворих на рак молочної залози, які не мають впливу 
іонізуючого випромінювання в анамнезі. Методи. 
Моле ку ляр но-генетичні методи дослідження. Непара-
мет рич ні дані оцінювали з використанням точного 
тесту Фішера в двобічному варіанті. Статистичний 
аналіз проводили з використанням пакету програми 
StatPlus Pro. Результати. Показано,що існують асо-
ціації носійства генетичних поліморфізмів rs2981582 
гена FGFR2, rs3803662 гена TOX3/LOC643714 з му-
таційним статусом генів BRCA1/2 жінок хворих на 
РМЗ без іонізуючого випромінювання в анамнезі. 
Висновки. Серед досліджених генетичних полімор-
фізмів достовірним виявили асоціацію між мінорним 
генотипом ТТгена TOX3/LOC643714 та позитивним 
статусом гена BRCA1. Не знайдено статистичної 
асоціації серед гомозигот за мажорними алелями та 
гетерозигот поліморфізмів генів FGFR2, TOX3/
LOC643714, з наявністю або відсутністю мутацій 
BRCA1/2 (p < 0,05).
К л юч ов і  с л ов а: рак молочної залози, генетичні 
поліморфізми, мутації BRCA1/2.
Определение ассоциации носительства 
генетических полиморфизмов с мутационным 
статусом генов brca1/2 при спонтанном раке 
молочной железы
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Цель. Проанализировать ассоциацию носительства 
генетических полиморфизмов генов FGFR2, TOX3 / 
LOC643714 с мутационным статусом генов BRCA1 / 2 
у женщин Украины, больных раком молочной железы, 
не имеющих влияния ионизирующего излучения в 
анамнезе. Методы. Молекулярно-генетические методы 
исследования. Непараметрические данные оценивались 
с использованием точного теста Фишера в двусторон-
нем варианте. Статистический анализ был проведен с 
использованием пакета программы StatPlus Pro. 
Результаты. Определена ассоциация носительства ге-
нетических полиморфизмов rs2981582 гена FGFR2, 
rs3803662 гена TOX3 / LOC643714 с мутационным 
статусом генов BRCA1 / 2 женщин, больных РМЖ, без 
ионизирующего излучения в анамнезе. Выводы. Среди 
исследованных генетических полиморфизмов была 
обнаружена ассоциация между минорным генотипом 
ТТгена TOX3 / LOC643714 и положительным статусом 
гена BRCA1. Не найдено статистической ассоциации 
среди гомозигот по мажорным аллелям и гетерозигот 
полиморфизмов генов FGFR2, TOX3 / LOC643714, с 
наличием или отсутствием мутаций BRCA1/2 (p < 0,05).
К л юч е в ы е  с л ов а: рак молочной железы, генети-
ческие полиморфизмы, мутации BRCA1/2.
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